
    
      The primary objective of this study is to evaluate the efficacy of LCM administered
      concomitantly with 1 to ≤3 Anti-Epileptic Drugs (AEDs) in subjects with epilepsy ≥4 years to
      <17 years of age who currently have uncontrolled partial onset seizures.

      The secondary objective is to evaluate the safety and tolerability of LCM in subjects ≥4
      years to <17 years of age.

      An additional objective is to evaluate the pharmacokinetics (PK) of LCM in subjects ≥4 years
      to <17 years of age.
    
  